Medicinal Products

EFFERALGAN VANILLA-STRAWBERRY 500 mg

Generic Drug Therapeutic Class: Diagnostic Products or Other Therapeutic Products
active ingredients: Paracetamol
laboratory: Upsa

Granule
box of 16
All forms

Indication

EFFERALGAN 500 mg Vanilla-Strawberry, granules in sachet is indicated for the symptomatic treatment of mild to moderate pain and / or febrile states.

Posology EFFERALGAN VANILLA-STRAWBERRY 500 mg Granules sachets box of 16

EFFERALGAN 500 mg Vanilla-Strawberry, granules in sachet is indicated for the symptomatic treatment of mild to moderate pain and / or febrile states.

Against indications

Hypersensitivity to the active substance or to any of the excipients listed under Composition .

Severe hepatocellular insufficiency or decompensated active liver disease.

Side effects Efferalgan Vanilla-strawberry

Very common (³ 1/10)

Frequent (³ 1/100 to <1/10)

Uncommon (1/1000 to <1/100)

Rare (1/10 000 to <1/1000)

Very rare (<1 / 10, 000)

Not known (can not be estimated from the available data)

Within each frequency group, adverse effects are presented in a decreasing order of severity.

Blood and lymphatic system disorders

Rare: anemia, nonhemolytic anemia, bone marrow depression, thrombocytopenia, leukopenia, neutropenia.

Vascular disorders

Rare: Edema.

Gastrointestinal disorders

Rare: acute and chronic pancreatitis, hemorrhage, abdominal pain, diarrhea, nausea, vomiting, liver failure, liver necrosis, jaundice

Skin and subcutaneous tissue disorders

Rare: pruritus, rash, secretion of sweat, purpura, angioedema, urticaria.

Renal and urinary disorders

Rare: nephropathies and tubular disorders

Paracetamol is widely used and reports of adverse effects are rare and usually associated with an overdose.

Nephrotoxic effects are uncommon and their reports were not associated with therapeutic doses except after prolonged administration.

Reporting of suspected adverse reactions

The reporting of suspected adverse reactions after authorization of the drug is important. It allows continuous monitoring of the benefit / risk ratio of the drug. Health professionals declare any suspected adverse reaction via the national reporting system: National Agency for the Safety of Medicines and Health Products (Ansm) and the network of Regional Pharmacovigilance Centers. Website: www.ansm.sante.fr.

Popular Posts

Category Medicinal Products, Next Article